Imatinib binding to human c-Src is coupled to inter-domain allostery and suggests a novel kinase inhibition strategy

Imatinib (Gleevec), a non-receptor tyrosine kinase inhibitor (nRTKI), is one of the most successful anti-neoplastic drugs in clinical use. However, imatinib-resistant mutations are increasingly prevalent in patient tissues and driving development of novel imatinib analogs. We present a detailed stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsutsui, Yuko, Deredge, Daniel, Wintrode, Patrick L., Hays, Franklin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969603/
https://www.ncbi.nlm.nih.gov/pubmed/27480221
http://dx.doi.org/10.1038/srep30832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969603/
https://www.ncbi.nlm.nih.gov/pubmed/27480221
http://dx.doi.org/10.1038/srep30832

Ejemplares similares